Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer

被引:68
作者
Huang, C
Taki, T
Adachi, M
Konishi, T
Higashiyama, M
Miyake, M
机构
[1] Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, Osaka 530, Japan
[2] Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Kita Ku, Osaka 530, Japan
[3] Ctr Adult Dis, Dept Surg, Osaka 537, Japan
关键词
p53; mutation; prognostic factor; SSCP; lung cancer;
D O I
10.1038/sj.onc.1201776
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study was performed to clarify the different effects of each mutant exon of p53 as indicators of a poor prognosis in patients with non-small cell lung cancer (NSCLC), Tumor tissues of 204 patients with NSCLC were analysed; 96 tumors were stage I, 22 stage II, and 86 stage III. DNA was extracted from frozen specimens and polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exon 5 to exon 8, Seventy-five patients with NSCLC (36.8%) had mutations in p53 which included 72 cases of missense mutations and three cases of non-missense mutations, The overall survival rate of patients with mutant p53 adenocarcinomas was strikingly worse than that of patients whose tumors had wild-type p53 (35.7% vs 53.8%; P = 0.041), but no significant difference in survival was found in the patients with NSCLC and squamous cell carcinoma, Mutations in exon 5 of p53 occurred in 33 cases (16.2%), mutation in exon 6 was detected in only one case (0.5%), mutations in exon 7 in 20 cases (9.8%), and mutations in exon 8 in 18 cases (8.8%), The overall survival rate of patients with mutations in exon 7 was worse than that of patients with wild-type p53 in NSCLCs and adenocarcinomas (42.9% vs 56.0%; P = 0.025 and 33.3% vs 53.8%; P = 0.048, respectively), whereas the overall survival of patients with mutations in exon 5 was almost the same as that of patients with wild-type p53, In addition, the overall survival rate of patients with mutations in exon 8 was strikingly worse than that of patients with wild-type p53 in NSCLCs, adenocarcinomas and squamous cell carcinomas (22.9% vs 56.0%; P < 0.001, 19.0% vs 53.8%; P = 0.004 and 33.3% vs 62.5%; P = 0.042, respectively). Multivariate analysis with the Cox regression model of patients with NSCLC, adenocarcinoma and squamous cell carcinoma indicated that mutations in exon 8 mere best correlated with the overall survival rate, followed by lymph node status (P < 0.001, P = 0.015 and P = 0.006, respectively), and mutations in exon 7 of NSCLC were also revealed to have good correlation, followed by lymph node status and mutations in exon 8 (P = 0.031), Mutation of p53 was a poor prognostic factor for adenocarcinoma as described previously, Moreover, mutations in exon 8 were more useful indicators of prognosis not only for adenocarcinoma but also for NSCLC, Worse overall survival of the patients with mutations in exon 8 of p53 was suggested to be associated with codon 273 mutations as well as mutations between codon 280 and 285 included into the H2 alpha helix corresponding to residues 278-286, These results suggested that abnormal conformation of H2 alpha helix might play an important role not only in the loss of normal function but also in the acquisition of tumorigenesis, Investigation of mutations in exon 8, especially codon 273 mutation and mutant H2 alpha helix was considered to be a clinically useful approach for determining the prognosis of patients with NSCLC.
引用
收藏
页码:2469 / 2477
页数:9
相关论文
共 42 条
[1]  
CHIBA I, 1990, ONCOGENE, V5, P1603
[2]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[3]  
CORDONCARDO C, 1995, AM J PATHOL, V147, P545
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]   MODULATION OF CELLULAR AND VIRAL PROMOTERS BY MUTANT HUMAN P53-PROTEINS FOUND IN TUMOR-CELLS [J].
DEB, S ;
JACKSON, CT ;
SUBLER, MA ;
MARTIN, DW .
JOURNAL OF VIROLOGY, 1992, 66 (10) :6164-6170
[6]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[7]  
EBINA M, 1994, CANCER RES, V54, P2496
[8]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[9]   WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO [J].
FARMER, G ;
BARGONETTI, J ;
ZHU, H ;
FRIEDMAN, P ;
PRYWES, R ;
PRIVES, C .
NATURE, 1992, 358 (6381) :83-86
[10]   K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer [J].
Fukuyama, Y ;
Mitsudomi, T ;
Sugio, K ;
Ishida, T ;
Akazawa, K ;
Sugimachi, K .
BRITISH JOURNAL OF CANCER, 1997, 75 (08) :1125-1130